Halozyme Therapeutics (NASDAQ:HALO) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen upgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday.

A number of other equities analysts have also issued reports on the stock. The Goldman Sachs Group reiterated a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday. TD Cowen boosted their target price on Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and a consensus target price of $78.80.

Halozyme Therapeutics Trading Down 2.2%

Shares of HALO opened at $71.71 on Friday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The company has a market cap of $8.43 billion, a price-to-earnings ratio of 15.10, a PEG ratio of 0.32 and a beta of 0.94. The stock has a fifty day moving average price of $68.93 and a two-hundred day moving average price of $68.45. Halozyme Therapeutics has a 52-week low of $47.50 and a 52-week high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The company had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. During the same quarter in the prior year, the business earned $1.27 earnings per share. The business’s revenue for the quarter was up 22.1% on a year-over-year basis. Analysts predict that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 16,569 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $68.92, for a total value of $1,141,935.48. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $48,844,913.48. This trade represents a 2.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the transaction, the director owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 41,398 shares of company stock valued at $2,861,352. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of Halozyme Therapeutics

Several hedge funds have recently added to or reduced their stakes in HALO. CWM LLC boosted its position in Halozyme Therapeutics by 2,136.0% during the third quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock valued at $1,751,000 after purchasing an additional 22,813 shares during the last quarter. Arbor Investment Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $1,316,000. Monument Capital Management bought a new position in shares of Halozyme Therapeutics in the third quarter valued at $2,015,000. Pacer Advisors Inc. increased its holdings in Halozyme Therapeutics by 2,054.7% during the third quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock worth $35,121,000 after buying an additional 456,649 shares during the last quarter. Finally, Cardinal Capital Management bought a new stake in Halozyme Therapeutics during the third quarter worth $1,303,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Preliminary 2025 results beat expectations and management raised 2026 outlook — the upbeat update helped push shares higher on Jan. 29 as revenue and profitability momentum improved, supporting the company’s longer‑term earnings trajectory. HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
• Positive Sentiment: Halozyme announced an acquisition of Surf Bio for up to $400M — this expands its pipeline/technology footprint tied to the ENHANZE platform and is a strategic revenue/pipeline bolt‑on that can accelerate growth if integrations and deal economics play out as expected. Halozyme Acquires Surf Bio for up to $400M
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and kept a $90 price target — a prominent sell‑side endorsement that supports upside vs. current levels and highlights confidence in the ENHANZE platform’s commercial contribution. H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating
• Positive Sentiment: Market commentary highlights HALO as a momentum name based on style scores and recent earnings/guidance — this can attract momentum and quant flows. Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: A valuation/markets piece examines whether HALO still offers value after multi‑year gains — useful context for longer‑term investors weighing current price vs. growth expectations. Is Halozyme Therapeutics (HALO) Offering Value After Strong Multi‑Year Share Price Gains
• Negative Sentiment: Zacks Research issued minor downward tweaks to several near‑term quarterly EPS estimates and kept a “Hold” stance — small cuts to Q2 2026 and Q3 2027 forecasts (and only tiny upward tweaks to other quarters) may have trimmed near‑term sentiment and contributed to selling/profit taking. (Zacks updates consolidated from analyst notes.)

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.